Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4

Goldman Sachs has upgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from a 'Sell' rating to 'Neutral.' The price target for the stock has been increased from $3 to $4, as stated by analyst Richard Law.